| SHP-2 as an essential component of tumor suppression and anoikis mediated by SIRPalpha1 in human breast carcinoma cells as well as in v-Src-transformed cells. | breast, |
| Data indicate that Shp2 is a tumor suppressor, and the decrease in Shp2 expression was a new prognostic marker in hepatocellular carcinoma (HCC). | liver, |
| PTPN11, which encodes tyrosine phosphatase Shp2, is a critical gene mediating cellular responses to hormones and cytokines. Recent experimental data suggest PTPN11/Shp2 acting as a tumor suppressor in hepatocarcinogenesis. | None |
| Ptpn11 is a tumour suppressor in cartilage, acting through a FGFR/MEK/ERK-dependent pathway in a novel progenitor cell population to prevent excessive Ihh production | None |
| Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. | leukemia, |
| Study demonstrates that PTPN11 plays oncogenic roles in melanoma and regulates RAS and GSK3beta signaling pathways. | skin, |
| Shp2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. | None |
| PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with Shp2 domain; diseases caused by mutations; role in hematopoiesis | None |
| PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. | None |
| analysis of the gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors | None |
| The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. | None |
| A G-quadruplex aptamer inhibits the phosphatase activity of oncogenic protein Shp2 in vitro. | None |
| Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. | None |
| SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival leading to myeloproliferative disease. | None |
| Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation. | None |
| Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). | None |
| Therapeutic potential of targeting the oncogenic SHP2 phosphatase. | None |
| Novel oncogenic PTPN11 mutations in myelodysplastic syndrome in Korean patients. | None |
| Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2. | None |
| Authors identify that miR-186 serves as a tumor suppressor in OSCC. Downregulation of this microRNA may lead to a higher expression of oncogenic factor SHP2, which leads to activation of growth promoting signaling. | None |